Who Paid My Doc
Audria Thomas
St Thomas, VI Medical Doctor
NPI 1356327886 CMS profile 1308493
9149 Estate Thomas, Paragon Medical Bldg. Ste 202, St Thomas, VI 00802
General payments
$35
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Audria Thomas of St Thomas, VI is reported in the CMS Open Payments database as having received $35 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $35 | 1 |
Beside peers
- Audria Thomas
- U.S. Virgin Islands median
- Middle half of U.S. Virgin Islands
- National median
In program year 2025, general payments to Audria Thomas were reported at $0. Among 33 U.S. Virgin Islands profiles paid that year, the median was $87 and the middle half received between $49 and $154.
Show as a table
| Year | Audria Thomas | U.S. Virgin Islands median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $120 | $46–$247 | $163 |
| 2020 | $35 | $66 | $28–$118 | $114 |
| 2021 | $0 | $92 | $32–$272 | $132 |
| 2022 | $0 | $119 | $67–$389 | $149 |
| 2023 | $0 | $91 | $27–$401 | $160 |
| 2024 | $0 | $100 | $47–$152 | $164 |
| 2025 | $0 | $87 | $49–$154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
112
Drug cost
$4,440
Branded share of claims
71.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 58 | $1,989 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 11 | $1,594 | |
| Fluticasone Propionate | Generic | 18 | $424 | |
| Losartan Potassium | Generic | 14 | $229 | |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | Brand | 11 | $204 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.